76/100BColgate-Palmolive Company stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Colgate-Palmolive Company is 101.00, 1.7% above the current price of 99.28. Their targets range from 95.00 to 112.00.
Of the 17 firms that rated Colgate-Palmolive Company in the past 12 months, 12 rate it buy or strong buy, 5 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 95.00 to 112.00, with an average of 101.00.
| Buy | 12 | |
| Hold | 5 | |
| Sell | 0 |
12-month price target
| Highest target | 112.00 |
| Average target | 101.00 |
| Lowest target | 95.00 |
| Current price | 99.28 |
Colgate-Palmolive Company price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Colgate-Palmolive Company price target and rating?
How analysts rate Colgate-Palmolive Company, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12 of 17 firms rate it buy now, against 11 of 15 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Colgate-Palmolive Company analyst upgrades, downgrades and price targets
The latest rating change came on 21 April 2026, when Rothschild& Co upgraded Colgate-Palmolive Company from Neutral to Buy. The most recent new target came from UBS on 2 November 2026: 112.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 2 Nov 2026 | UBS Peter Grom | Reiterated · Buy | 106.00 → 112.00 | +5.7% | 95.29 |
| 15 Oct 2026 | UBS | — | 109.00 → 106.00 | -2.8% | 94.14 |
| 21 Sept 2026 | Piper Sandler | Reiterated · Overweight | 92.00 → 95.00 | +3.3% | 87.47 |
| 3 Aug 2026 | RBC Capital Nik Modi | Reiterated · Outperform | 102.00 → 104.00 | +2.0% | 91.67 |
| 3 Aug 2026 | Deutsche Bank | — | 99.00 → 101.00 | +2.0% | 91.31 |
| 3 Aug 2026 | Morgan Stanley | — | 100.00 → 104.00 | +4.0% | 92.40 |
| 3 Aug 2026 | UBS | Reiterated · Buy | 100.00 → 109.00 | +9.0% | 92.29 |
| 8 Jul 2026 | Wells Fargo Chris Carey | Reiterated · Equal Weight | 92.00 → 95.00 | +3.3% | 95.03 |
| 11 Jun 2026 | Bernstein Cristian Rios | — | 96.00 | — | 89.39 |
| 4 May 2026 | UBS | Reiterated · Buy | 93.00 → 100.00 | +7.5% | 85.50 |
| 4 May 2026 | Deutsche Bank Steve Powers | — | 86.00 → 99.00 | +15.1% | 85.79 |
| 21 Apr 2026 | Redburn Partners | — | 93.00 → 100.00 | +7.5% | 83.53 |
| 21 Apr 2026 | Rothschild& Co | Upgraded · Neutral → Buy | — | — | — |
| 21 Apr 2026 | Rothschild & Co | Upgraded · Neutral → Buy | — | — | — |
| 14 Apr 2026 | Barclays Lauren Lieberman | Reiterated · Equal Weight | 88.00 → 79.00 | -10.2% | 83.94 |
| 9 Apr 2026 | RBC Capital | — | 88.00 → 102.00 | +15.9% | 86.04 |
| 8 Apr 2026 | Piper Sandler | Reiterated · Overweight | 96.00 → 92.00 | -4.2% | 85.55 |
| 8 Apr 2026 | Wells Fargo Chris Carey | Reiterated · Equal Weight | 94.00 → 92.00 | -2.1% | 85.55 |
| 30 Mar 2026 | Deutsche Bank | Upgraded · Hold → Buy | — | — | — |
| 20 Feb 2026 | Goldman Sachs Bonnie Herzog | — | 94.00 → 100.00 | +6.4% | 95.09 |
| 13 Feb 2026 | Redburn Partners | — | 93.00 | — | 96.17 |
| 3 Feb 2026 | Barclays Lauren Lieberman | Reiterated · Equal Weight | 83.00 → 88.00 | +6.0% | 91.89 |
| 2 Feb 2026 | Morgan Stanley Dara Mohsenian | Reiterated · Overweight | 87.00 → 100.00 | +14.9% | 90.29 |
| 1 Feb 2026 | Wells Fargo | — | 86.00 → 94.00 | +9.3% | 90.29 |
| 31 Jan 2026 | Goldman Sachs Bonnie Herzog | — | 94.00 | — | 90.29 |
| 30 Jan 2026 | Piper Sandler | — | 88.00 → 96.00 | +9.1% | 89.45 |
| 16 Jan 2026 | Barclays Lauren Lieberman | — | 82.00 → 83.00 | +1.2% | 84.32 |
| 14 Jan 2026 | UBS Peter Grom | Reiterated · Buy | 92.00 → 93.00 | +1.1% | 83.27 |
| 13 Jan 2026 | Wells Fargo | Upgraded · Underweight → Equal Weight | 86.00 | — | 81.93 |
| 7 Jan 2026 | Piper Sandler | Upgraded · Neutral → Overweight | — | — | — |
| 6 Jan 2026 | Piper Sandler | — | 84.00 → 88.00 | +4.8% | 77.20 |
| 16 Dec 2025 | Jefferies | — | 85.00 | — | 78.95 |
| 11 Dec 2025 | Argus Research | Downgraded · Buy → Hold | — | — | — |
| 9 Dec 2025 | RBC Capital | Upgraded · Sector Perform → Outperform | 88.00 | — | 76.11 |
Colgate-Palmolive Company EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Colgate-Palmolive Company's EPS to grow 18.8% a year until 2028. Over the last 5 years it fell 3.5% a year, and over the last 3 years it grew 7.3%.
Analysts expect Colgate-Palmolive Company's revenue to grow 3.6% a year until 2028, about as fast as over the last 5 years (4.4% a year) and the last 3 years (4.3%).
Revenue
EPS
Does Colgate-Palmolive Company beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 3.7% off the result, either way, and their revenue estimate 1.1%, over the last 12 quarters.
- EPS beats
- 69 / 136
- Revenue beats
- 70 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +3.7%
- Since
- February 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Oct 2026 | 0.93 | 0.97 | +4.8% | 5.34B | 5.37B | +0.6% |
| Q2 FY2026 | 31 Jul 2026 | 0.95 | 0.99 | +4.5% | 5.36B | 5.36B | +0.1% |
| Q1 FY2026 | 1 May 2026 | 0.94 | 0.97 | +2.9% | 5.22B | 5.32B | +2.1% |
| Q4 FY2025 | 30 Jan 2026 | 0.91 | 0.95 | +4.2% | 5.12B | 5.23B | +2.1% |
| Q3 FY2025 | 31 Oct 2025 | 0.89 | 0.91 | +2.4% | 5.13B | 5.13B | +0.1% |
| Q2 FY2025 | 1 Aug 2025 | 0.90 | 0.92 | +2.6% | 5.04B | 5.11B | +1.5% |
| Q1 FY2025 | 25 Apr 2025 | 0.86 | 0.91 | +6.3% | 4.87B | 4.91B | +0.9% |
| Q4 FY2024 | 31 Jan 2025 | 0.90 | 0.91 | +1.1% | 4.98B | 4.95B | -0.7% |
| Q3 FY2024 | 25 Oct 2024 | 0.89 | 0.91 | +2.2% | 5.01B | 5.03B | +0.5% |
| Q2 FY2024 | 26 Jul 2024 | 0.87 | 0.91 | +4.6% | 5.00B | 5.06B | +1.1% |
| Q1 FY2024 | 26 Apr 2024 | 0.81 | 0.86 | +6.2% | 4.96B | 5.07B | +2.1% |
| Q4 FY2023 | 26 Jan 2024 | 0.85 | 0.87 | +2.4% | 4.89B | 4.95B | +1.2% |
Colgate-Palmolive Company stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Colgate-Palmolive Company's earnings keep growing at the 6.1% a year analysts expect to FY2028, it would earn about 4.97 a share in FY2030. At the P/E it has traded at over the last five years (25.8 to 38.6) that is 127.91 to 191.57 a share, or 159.97 at its average P/E of 32.2. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 3.92 | 100.85 | 126.13 | 151.04 |
| FY2027 | 4.10 | 105.64 | 132.12 | 158.21 |
| FY2028 | 4.41 | 113.58 | 142.05 | 170.10 |
| FY2029 (extrapolated) | 4.68 | 120.53 | 150.74 | 180.52 |
| FY2030 (extrapolated) | 4.97 | 127.91 | 159.97 | 191.57 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 6.1% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (25.8, 32.2, 38.6).
Is Colgate-Palmolive Company stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Colgate-Palmolive Company's P/E of 38.6 is near the top of its 5-year range (20.9 to 42.9, median 32.5). Analysts expect faster growth than in recent years, which can explain part of the high P/E. At its usual P/E (32.5 × EPS of 2.57), Colgate-Palmolive Company's fair value is 83.56; the price, 99.28, is 18.8% above it. Its forward P/E, on the consensus for FY2026, is 25.4.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (20.9 and 42.9). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 38.57
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 32.46
- Five-year P/E range
- 20.9 – 42.9
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 25.35
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 6.30
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +1.7%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.850 | 71.4258Price 35.85193 | +99.2% | |
| 29.050 | 56.2634Price 29.0596 | +93.7% | |
| 241.000 | 464.49205Price 241.00627 | +92.7% | |
| 123.590 | 237.24178Price 123.59297 | +92.0% | |
| 161.400 | 305.52159Price 161.40396 | +89.3% | |
| 157.460 | 297.58169Price 157.46471 | +89.0% | |
| 217.560 | 405.38304Price 217.56507 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.